WCLC 2025 - Posters & ePosters-P3.18.76 Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer

P3.18.76 Efficacy and Safety of Cross-Line Adebrelimab Combined With Apatinib and Nab-Paclitaxel in Recurrent Small Cell Lung Cancer

Back to course

Pdf Summary

This prospective, multicenter, single-arm study (ChiCTR2300072520) evaluated the efficacy and safety of continuing adebrelimab (an anti-PD-L1 antibody) beyond progression in combination with apatinib (a VEGFR2 inhibitor) and nab-paclitaxel for patients with relapsed extensive-stage small cell lung cancer (SCLC) after first-line treatment with adebrelimab plus chemotherapy. Twelve patients with relapsed SCLC who progressed after first-line adebrelimab-based therapy were enrolled between December 2023 and February 2025. Patients had a median age of 61.5 years, with ECOG performance status 0–1 and measurable disease; 25% had brain metastases.<br /><br />The treatment regimen consisted of adebrelimab 1200 mg IV every 3 weeks, apatinib 250 mg orally daily, and nab-paclitaxel 200 mg/m^2 IV every 3 weeks for 2–4 cycles followed by maintenance therapy. The primary endpoint was objective response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), disease control rate (DCR), duration of response, and safety.<br /><br />Results showed an unconfirmed ORR of 66.7% (8/12 patients) and a DCR of 83.3%. After a median follow-up of 6.4 months, the median PFS was 6.2 months (95% CI: 4.9–7.5), exceeding typical second-line regimens which achieve ~25% ORR and 6–8 months OS. Treatment-related adverse events (TRAEs) occurred in 75% of patients, with 41.7% experiencing grade 3 TRAEs; most common severe toxicities were neutrophil and white blood cell count decreases. No new safety signals emerged.<br /><br />In conclusion, continuing immune checkpoint inhibition with adebrelimab combined with apatinib and nab-paclitaxel demonstrated promising antitumor activity and manageable toxicity in relapsed SCLC post-immunotherapy progression, offering a novel therapeutic option in this difficult-to-treat setting.

Asset Subtitle

Hongbo Wu

Meta Tag

Speaker Hongbo Wu

Topic Clinical Trials in Progress

Keywords

adebrelimab

apatinib

nab-paclitaxel

small cell lung cancer

SCLC

immune checkpoint inhibition

anti-PD-L1 antibody

VEGFR2 inhibitor

relapsed extensive-stage SCLC

second-line therapy